Similarly, since crizotinib became the first ALK inhibitor approved in 2012 [7], the development of newer ALK inhibitors continued, adding EMA approval of lorlatinib in 2019 for advanced ALK-positive NSCLC after the failure of other ALK inhibitors, as well as alectinib in 2017 for second-line and in 2020 for first-line treatment [8]. Here, ALK is linked to non-small cell lung carcinoma.